Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Date
2020
Author
Yildiz, Birol
Hacioglu, Muhammet Bekir
Kostek, Osman
Karabulut, Senem
SEZGİN GÖKSU, SEMA
Alandag, Celal
Akagunduz, Baran
Bilgetekin, Irem
Caner, Burcu
ŞAHİN, AHMET BİLGEHAN
Kose, Fatih
Kaplan, Muhammet Ali
Gulmez, Ahmet
DOĞAN, ENDER
Guven, Deniz Can
Gurbuz, Mustafa
Ergun, Yakup
KARAAĞAÇ, MUSTAFA
Demiray, Atike Gokcen
Turker, Sema
Sakalar, Teoman
Ozkul, Ozlem
Telli, Tugba Akin
Sahin, Suleyman
KILIÇKAP, SAADETTİN
Bilici, Ahmet
ERDOĞAN, BÜLENT
ÇİÇİN, İRFAN
Tastekin, Didem
Metadata
Show full item record
Abstract
Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.
URI
http://hdl.handle.net/20.500.12627/4404
Collections